Xylitol Is Sold as a Clean Upgrade. Why Is It Making Blood More Likely to Clot?
New data from 17,710 people, including the Canadian Longitudinal Study on Aging, links higher blood xylitol to more heart attacks, strokes and deaths. Here is what the clotting research shows, and where the critics have a point.

If you spend real money and attention staying ahead of your health, a bag of white sweetener probably doesn’t register as a cardiovascular decision. You track your training. You know your ApoB and your Lp(a). You don’t wait for symptoms before you take blood pressure seriously. Then you stir a “natural,” low-carb, tooth-friendly sweetener into your coffee, or bake with it by the cup. It was sold to you as the obvious upgrade over sugar.
In late August, a team led by Dr. Marco Witkowski of Charité University Hospital in Berlin presented data at the European Society of Cardiology Congress in Munich that makes that habit harder to defend. They measured blood xylitol in 17,710 people from two long-running community cohorts, and one of them is Canadian. The Canadian cohort is the Canadian Longitudinal Study on Aging. Over six years, people in its highest quarter of xylitol levels had a 57% higher risk of heart attack, stroke or death than people in the lowest quarter. That held after adjusting for age, sex, smoking, lipids, diabetes and hypertension. In EPIC-Norfolk, an English cohort followed for 30 years, the gap was smaller at 18%, and it pointed the same way.
Those numbers haven’t been through peer review yet. Witkowski says his lab work argues for a causal link, and the ESC’s own commentator, Professor Dan Atar, noted that causality is hard to infer from observational data. What makes the numbers hard to wave away is where they land. Two years earlier, the same group found the same signal in 3,306 cardiac patients at Cleveland Clinic. They then showed in human blood, in mice and in ten healthy volunteers how xylitol makes platelets quicker to clot. The 2026 data moves that finding out of the cardiology clinic and into the general population, including middle-aged and older Canadians. One association is a hypothesis. Three lines of evidence from two continents, all pointing at the same molecule, is a pattern worth acting on while the trials catch up.
Where the signal first showed up
The original paper, published in the European Heart Journal in June 2024, followed people having elective cardiac evaluation at Cleveland Clinic. The team found the association first in 1,157 patients using untargeted metabolomics, a broad screen of small molecules in the blood. They then confirmed it in a second group of 2,149 with a purpose-built mass spectrometry assay that separates xylitol from look-alike sugar alcohols. In that validation cohort, people in the top third of fasting xylitol had an adjusted hazard ratio of 1.57 (95% CI 1.12 to 2.21) for heart attack, stroke or death over three years. These weren’t healthy volunteers, and the table shows how sick the room was.

| Characteristic | Discovery cohort (n = 1,157) | Validation cohort (n = 2,149) |
|---|---|---|
| Age, years | 65 (56-72) | 63 (55-72) |
| Male | 64% | 64% |
| BMI, kg/m² | 28.4 (25.4-32.1) | 28.4 (25.5-32.2) |
| Diabetes mellitus | 22% | 22% |
| Hypertension | 72% | 70% |
| Current smoking | 14% | 13% |
| Systolic blood pressure, mmHg | 132 (119-146) | 132 (119-146) |
| History of cardiovascular disease | 76% | 78% |
| History of coronary artery disease | 76% | 75% |
| History of myocardial infarction | 46% | 40% |
| One coronary vessel with at least 50% stenosis | 22% | 19% |
| Two coronary vessels with at least 50% stenosis | 19% | 20% |
| Three or more coronary vessels with at least 50% stenosis | 30% | 32% |
| History of heart failure | 17% | 19% |
| eGFR, mL/min/1.73m² | 89.8 (75.7-99.1) | 90.4 (75.4-100.3) |
| LDL cholesterol, mg/dL | 96 (80-116) | 96.0 (77.0-117) |
| HDL cholesterol, mg/dL | 34 (29-41) | 34.3 (28.2-41.7) |
| Total cholesterol, mg/dL | 163 (143-188) | 161 (139-187) |
| Triglycerides, mg/dL | 122 (84-171) | 114 (84.0-163) |
| hsCRP, mg/L | 2.31 (0.97-5.39) | 2.30 (1.01-5.42) |
| Baseline medication | ||
| Statins | 61% | 59% |
| Aspirin | 77% | 72% |
| Anti-diabetic drugs | 9% | 12% |
| ACE inhibitors/ARBs | 50% | 50% |
| Calcium channel blockers | 19% | 19% |
| Diuretics | 19% | 21% |
Baseline characteristics from Witkowski et al., 2024. Values are median (interquartile range) unless stated otherwise.
Three quarters of these patients already had coronary artery disease, and close to a third had at least three narrowed coronary vessels. Most were on aspirin or a statin. For anyone with plaque, a prior event, diabetes, kidney disease, a high ApoB, elevated Lp(a) or a family history nobody has taken seriously, that’s the population that matters. A ruptured plaque in a coronary artery becomes a heart attack when platelets pile onto it. A small shift toward clotting does its damage in exactly these arteries. The useful question for that reader is why an optional sweetener with a plausible clotting mechanism belongs in a daily routine while the answer is still open.
What xylitol does to a platelet
The lab work is what turned a statistical association into a biological story. Added to human platelet-rich plasma, whole blood and isolated platelets at the concentrations found in fasting participants, xylitol made platelets respond more strongly to normal activation signals. In mice whose carotid arteries were injured with ferric chloride, raising blood xylitol to human-like levels shortened the time until the artery clotted shut. Hazen and Witkowski spelled out the mechanism in a later reply to critics: neither xylitol nor erythritol triggers a clot on its own. Both lower the threshold, so a platelet that would have ignored a minor signal joins the clot instead. That’s a hair trigger on a system that already fires every time a plaque cracks.
Then came the experiment that matters most for anyone holding a bag of the stuff. Ten healthy volunteers drank 30 g of xylitol dissolved in water. According to the paper, that’s about what you’d get from a xylitol-sweetened bakery item, a pint of xylitol ice cream or several pieces of xylitol candy. Some products use it at full sugar-replacement levels. Thirty minutes later, median plasma xylitol had gone from about 0.3 µM to 312 µM, roughly a thousandfold rise, and platelet responsiveness was up in all ten people. The researchers report that xylitol stays above baseline for more than four to six hours after a dose like that. Nobody has measured whether the platelet effect lasts as long. If it does, a sweetened coffee in the morning and a dessert at night would keep platelets primed for much of the day.
The case against, taken seriously
The findings drew real pushback, and some of it lands. In a 2025 European Heart Journal commentary, three researchers argued that the cohort data mostly reflect xylitol the body makes itself. Every sample was drawn after an overnight fast. They pointed out that the volunteer study had no placebo arm and measured platelets at a single time point, and that platelet aggregation shifts with exercise and food. They also noted that intravenous xylitol is approved in Germany at up to 3 g per kilogram per day. The only serious harm they cited was kidney oxalate deposits at IV doses above 300 g a day. One of the three, Arduino Arduini, founded and is a major shareholder of Iperboreal Pharma, which is developing XyloCore, a peritoneal dialysis fluid that replaces most of its glucose with xylitol. He declared that interest in the commentary, and the other two authors, both at the University of Basel, declared none.
Hazen and Witkowski answered each point. Their companion study on erythritol, published in Arteriosclerosis, Thrombosis, and Vascular Biology in August 2024, did include a comparison. Thirty grams of erythritol raised platelet reactivity, and the same dose of glucose did not. They argued that IV xylitol is used only occasionally in intensive care and isn’t recommended by the guidelines they cite. Higher blood levels, in their view, would only stretch the window of platelet priming. The endogenous argument also cuts both ways. If high blood xylitol is harmful wherever it comes from, a sweetener that raises it a thousandfold in half an hour is the last thing someone with that biology needs. The 2026 samples were fasting too, so they can’t settle where the xylitol came from, but they do show the signal reaches well beyond cardiac patients.
Nobody has run the trial that would end the argument. It would be a long, placebo-controlled study counting heart attacks and strokes in people assigned to eat xylitol or avoid it. Witkowski has said that intervention studies testing different amounts are needed to define a safe threshold, and that they haven’t been done. Until they are, there’s no safe dose anyone can quote you. That gap is a reason to step back from bulk use, and a poor reason to lean further in.
“Natural birch sugar” is a marketing story

Xylitol occurs in small amounts in fruit and vegetables, and the body makes some as a by-product of glucose metabolism. Neither fact tells you how the white crystals in a bulk bag were made. Commercial xylitol usually starts as hardwood or corn-cob residue rich in xylan, a plant fibre. That material is broken down to release xylose, which is purified and then chemically reduced to xylitol by catalytic hydrogenation under heat and hydrogen pressure. The product is crystallized and purified again before it reaches the shelf, and while newer fermentation methods exist, hydrogenation is still the standard commercial route.
There’s nothing wrong with industrial processing as such, and plenty of lifesaving medicines come out of a reactor. The trouble is that “comes from birch” says nothing about safety. The ESC release notes that xylitol is added to foods, drinks and oral care products at more than a thousand times the amounts found in nature. Its reputation rests on properties that are real: fewer calories, a low glycaemic impact, and better for teeth than sugar. None of them says anything about the heart.
Where the exposure hides
Xylitol shows up in powdered sweeteners, low-sugar baking, keto desserts, protein bars, candy, gum, mints, toothpaste and some supplements, sometimes labelled as birch sugar. The exposure that matches the 30 g test is bulk use. Think coffee sweetener, ice cream, baked goods, and the daily “healthy” snack someone chose because it looked metabolically responsible. A piece of gum, or toothpaste you spit out, sits far below that dose, and lumping the two together helps nobody. Witkowski’s own advice is narrow and practical: avoid the larger amounts that come mostly from heavily sweetened processed products.
A higher standard for people with something to lose
If you have known atherosclerosis or a high-risk profile, a daily high-dose xylitol habit is a poor bet. The bigger drivers come first: smoking, blood pressure, ApoB, diabetes, fitness, sleep apnea, and taking your medication as prescribed. Prevention also means clearing the avoidable risks beneath those, and this one costs nothing to drop. Atherosclerosis builds quietly for years, and a clot is usually the event that turns it into an emergency. A sweetener that makes platelets quicker to clot would need a large benefit to earn its place, and for most people it doesn’t have one.
The standard should be higher than “nobody has proved it killed anyone.” When the exposure is optional and the benefit is small, waiting for a consensus statement is a decision to keep taking the risk in the meantime. Read labels, and don’t confuse “sugar-free” with “risk-free.” The next things to watch are the peer-reviewed paper on the CLSA and EPIC-Norfolk data, and whether anyone funds the placebo-controlled event trial that would settle this. At Plunge, we look for exactly these gaps between what a product promises and what the evidence has earned. That’s how preventive care becomes more than an annual physical. Explore the Plunge approach or join the waitlist.
References
-
Witkowski M, Nemet I, Li XS, et al. Xylitol is prothrombotic and associated with cardiovascular risk. European Heart Journal. 2024;45(27):2439-2452. DOI: 10.1093/eurheartj/ehae244. pubmed.ncbi.nlm.nih.gov/38842092/
-
European Society of Cardiology. Xylitol may increase the risk of cardiovascular events. Press release, 26 August 2026, on Witkowski M, “The association of xylitol and incident cardiovascular events: the CLSA and EPIC-Norfolk cohort studies,” ESC Congress 2026, Munich. escardio.org/news/press/press-releases/xylitol-may-increase-the-risk-of-cardiovascular-events/
-
Wölnerhanssen BK, Meyer-Gerspach AC, Arduini A. Xylitol exposure and cardiovascular risk. European Heart Journal. 2025;46(3):328. DOI: 10.1093/eurheartj/ehae730.
-
Witkowski M, Hazen SL. Erythritol and xylitol and cardiovascular disease risk: a growing concern. European Heart Journal. 2025;46(29):2931-2932. DOI: 10.1093/eurheartj/ehae729.
-
Witkowski M, Wilcox J, Province V, et al. Ingestion of the non-nutritive sweetener erythritol, but not glucose, enhances platelet reactivity and thrombosis potential in healthy volunteers. Arteriosclerosis, Thrombosis, and Vascular Biology. 2024. DOI: 10.1161/ATVBAHA.124.321019.
-
Sukkasem C, et al. A Comprehensive Review on Xylitol Production: Experimental and Theoretical Insights, Research Gaps, and Future Perspectives. Advanced Energy and Sustainability Research. 2026;7(6). DOI: 10.1002/aesr.70208.
-
Dasgupta D, Bandhu S, Adhikari DK, Ghosh D. Challenges and prospects of xylitol production with whole cell bio-catalysis: a review. Microbiological Research. 2017;197:9-21. DOI: 10.1016/j.micres.2016.12.012.